© 2021 MJH Life Sciences and Contagion Live. All rights reserved.
© 2021 MJH Life Sciences™ and Contagion Live. All rights reserved.
July 14, 2021
The MOVe-OUT study will continue to the phase 3 portion and evaluate 800 mg of the therapy administered twice daily.
July 13, 2021
Those taking methotrexate had lower seroconversion rates compared to controls.
July 12, 2021
While infection risk is not eliminated, the vaccine still provided significant protection.
The second wave in South Africa was larger and saw the Beta lineage dominate.
Investigators followed patients with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) for 6 months to review their outcomes.
July 11, 2021
A Swiss population-based study showed more people in socioeconomically challenged places tested positive more frequently, saw higher hospitalizations, and greater mortality rates than those in higher socioeconomic places.
Azithromycin versus standard care in patients with mild-to-moderate COVID-19, did not reduce the risk of hospital admission or mortality.
May 27, 2020
A dosage of 250 mg twice daily for 10 days was confirmed for the next phase of trials after achieving initial and sustained cure in 100% of patients.
May 19, 2020
Oral ibrexafungerp could cut hospital stays for patients with invasive candidiasis infections.
May 07, 2020
It is known that the type of respiratory specimen, sampling environmental factors, and time from symptom onset impact the sensitivity of rapid influenza diagnostic tests.